Liraglutide
Liraglutide (Victoza/Saxenda) was one of the first GLP-1 receptor agonists with extensive long-term safety data. While producing less weight loss than newer agents, it has the longest cardiovascular outcomes data and pediatric approval.
Evidence Summary
Liraglutide has one of the deepest evidence bases among GLP-1 receptor agonists. The LEADER trial (n=9,340) showed a 13% reduction in major adverse cardiovascular events over a median 3.8 years, and the SCALE program demonstrated 5-8% weight loss. Recent research has widened its profile: a 2025 Cochrane systematic review of adults living with obesity confirmed clinically meaningful weight and cardiometabolic benefit; the SCALE Kids trial (New England Journal of Medicine, 2024) showed liraglutide 3.0 mg reduced BMI by about 6% versus placebo in children aged 6 to under 12 over 56 weeks; and the phase 2b ELAD trial in mild-to-moderate Alzheimer's disease (Nature Medicine, 2025; 204 patients, 52 weeks) did not meet its primary endpoint of change in cerebral glucose metabolism but reported roughly 18% slower cognitive decline on an executive-function composite and about 50% less brain-volume loss across several gray-matter regions on secondary and exploratory measures. Liraglutide is not approved for Alzheimer's disease; these neurological findings are early and require confirmation. Summary of published research, not a treatment claim.
Evidence Scale
Mechanism of Action
GLP-1 receptor agonist with 97% amino acid homology to native GLP-1. Binds to albumin for extended half-life (~13 hours). Activates pancreatic GLP-1 receptors to enhance glucose-dependent insulin secretion and suppress glucagon. Delays gastric emptying and reduces appetite via hypothalamic signaling. GLP-1 receptors are also expressed in the brain, providing a mechanistic rationale for the anti-neuroinflammatory and neuroprotective effects now under investigation.
Who Is This For?
Type 2 diabetes. Weight management (BMI criteria). Adolescent obesity (age 12+). Patients preferring established safety data over maximum efficacy.
Protocol & Dosing
Dose
Victoza (T2D): Start 0.6mg daily for 1 week, then 1.2mg, max 1.8mg. Saxenda (weight): Start 0.6mg daily, increase by 0.6mg weekly to target 3.0mg daily.
Frequency
Daily injection
Duration
Ongoing / Long-term
Protocol Summary
Daily subcutaneous injection. Requires daily dosing unlike newer weekly options. Well-established safety profile with 10+ years of real-world data.
Interactions & Precautions
Contraindications
- Medullary thyroid carcinoma history
- MEN2
- Pancreatitis history
- Pregnancy
Potential Risks
- •Thyroid tumor risk (preclinical)
- •Pancreatitis
- •Gallbladder disease
Potential Side Effects
Practitioner Notes
Clinical annotations from Dr. Goel
Best option when long-term safety data is priority. Daily injection may reduce adherence vs weekly options. Good stepping stone before newer, more potent agents. Consider switching to semaglutide if weight loss plateau. Note the emerging brain-health data (ELAD, 2025), but counsel patients that liraglutide is not approved for cognitive indications and the signal is preliminary.
Dr. Sanjeev Goel
Chief Medical Officer, Peak Human
Latest Evidence
2024-2026: what the newest liraglutide trials show
Liraglutide is the longest-studied GLP-1 receptor agonist, and recent research has widened its profile well beyond glucose control. A 2025 Cochrane systematic review of adults living with obesity confirmed clinically meaningful weight loss and cardiometabolic benefit, consistent with the SCALE program's 5-8% weight reduction and the LEADER trial's 13% drop in major cardiovascular events. In 2024, the SCALE Kids trial (New England Journal of Medicine) extended efficacy to children aged 6 to under 12, where liraglutide 3.0 mg reduced BMI by about 6% versus placebo over 56 weeks.
The most talked-about new signal is neurological. The phase 2b ELAD trial (Nature Medicine, 2025; 204 patients with mild-to-moderate Alzheimer's disease, 52 weeks) did not meet its primary endpoint - change in the brain's glucose metabolic rate - but on secondary and exploratory measures the liraglutide group showed roughly 18% slower decline on an executive-function composite and about 50% less brain-volume loss across several gray-matter regions (temporal lobe 696 mm3, p<0.001; total gray matter 7,274 mm3, p=0.002 less atrophy vs placebo). By contrast, the larger EVOKE program with once-weekly semaglutide did not show a clear cognitive benefit, so the GLP-1-and-brain story remains unsettled.
Liraglutide is FDA-approved for type 2 diabetes and weight management (including adolescents 12+), but it is not approved for Alzheimer's disease; the cognitive findings are early and need confirmation. These are summaries of published research, not treatment claims. Educational information, not medical advice - discuss any GLP-1 therapy with a qualified clinician.
Phase 2b RCT · 204 patients · 52 weeks · mild-to-moderate Alzheimer's
ELAD trial - liraglutide vs placebo, secondary & exploratory outcomes
Longer bar = greater benefit vs placebo →
Source: ELAD trial, Nature Medicine (2025); NCT01843075, 204 patients, 52 weeks. The primary endpoint (change in cerebral glucose metabolism) was not met; the values shown are favorable secondary and exploratory outcomes. The ~50% figure is an approximate average across affected gray-matter regions (exact: temporal lobe 696 mm3, p<0.001; total gray matter 7,274 mm3, p=0.002 less atrophy vs placebo). Liraglutide is not approved for Alzheimer's disease. Educational summary of published research, not a treatment claim.
Related on Peak Human
Semaglutide
The once-weekly GLP-1 with greater weight loss - and a contrasting brain-health readout.
Retatrutide
Investigational triple agonist - the most potent incretin in trials.
Metformin
Foundational metabolic-longevity agent, often paired with GLP-1s.
Weight Loss
Goal-based protocols where GLP-1 therapy fits.
Optimization at Peak Human
Physician-supervised, biomarker-tracked optimization programs.
Oral GLP-1
A GLP-1 option in the shop, via an independent third-party supplier.
Key references: Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trial (ELAD) - Nature Medicine (2025) · Liraglutide for children 6 to <12 years of age with obesity (SCALE Kids) - New England Journal of Medicine (2024) · Liraglutide for adults living with obesity - Cochrane Database of Systematic Reviews (2025) · Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER) - New England Journal of Medicine (2016)
Cost & Access
Cost Range
$$$
Accessibility
Availability varies by location
Sample member
Longevity Operator
One number for your longevity journey.
FICO for credit. PHS for longevity. Eight biological domains collapsed into one provable score — intuitive at a glance, rigorous underneath.
- Metabolic
- Hormonal
- Cardiovascular
- Brain / Cognitive
- Sleep
- Musculoskeletal
- Gut
- Immunity / Inflammation